Matches in Nanopublications for { ?s ?p "[To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-na�ve subjects through 144 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion description "[To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-na�ve subjects through 144 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_provenance.
- NP1233156.RATANh-VJvEOx7fDhz_CpHFBwk6RFQNOUgH6dHXKNHe9c130_assertion description "[To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-na�ve subjects through 144 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233156.RATANh-VJvEOx7fDhz_CpHFBwk6RFQNOUgH6dHXKNHe9c130_provenance.
- NP713020.RAiMmJ-f1UrVASO85pyYF6AkGCaTfzSkSOjyLcOC2g2-s130_assertion description "[To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-na�ve subjects through 144 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP713020.RAiMmJ-f1UrVASO85pyYF6AkGCaTfzSkSOjyLcOC2g2-s130_provenance.
- NP1233157.RANcMYvnf7m7d7w0einQDwH4oiFnWqmyqUVferUr892TE130_assertion description "[To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-na�ve subjects through 144 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233157.RANcMYvnf7m7d7w0einQDwH4oiFnWqmyqUVferUr892TE130_provenance.